Condition: Triple Negative Breast Cancer · HER2-positive Breast Cancer · Hormone Receptor-positive Breast Cancer · Sponsor: H. Lee Moffitt Cancer Center and Research Institute
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
This description comes directly from the study's public registry record.
Robin Dowell · 813-745-0393 · Robin.Dowell@moffitt.org
Always discuss trial participation with your own doctor first.
| Morton Plant Mease- Baycare | Clearwater, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05115474